Summary

The veterinary vaccines market is expected to register a CAGR of about 9.1%, during the forecast period.

The market has been impacted majorly by the COVID-19 pandemic. There are a few known COVID-19 infections among pets, globally. According to the American Veterinary Medical Association, one cat in Belgium tested positive and recovered after nine days. Numerous animal husbandry companies have been affected due to the outbreak, especially in many of the major outbreak zones, including China, the United States, Italy, Spain, France, Germany, and other European countries, which, in turn, has impacted the animal vaccines market, as all research and also breeding programs have been put on hold.​

Supply disruption and medicine shortages of veterinary medicines have been observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export bans, and increased demand for medicine, for the treatment of COVID-19. Governments are taking measures to mitigate the supply of medicines. For instance, the European Medicines Agency issued guidance for companies responsible for veterinary medicines, with respect to the adaptations to the regulatory framework, primarily to address the challenges faced during this pandemic situation.​

Anthrax is one of the most common livestock diseases in the world. According to a report published by WHO (World Health Organization), although national programs have resulted in the containment of anthrax globally, it is still prevalent, primarily due to the lack of experience of the most recent generations of veterinarians in identifying and reporting the disease, and the discontinuation of vaccination against the disease.

Livestock diseases are contributing to a set of problems within livestock production systems. These problems include productivity losses, uncertain food security, and loss of income, among others, which are adversely affecting human health. Livestock disease management can reduce disease through the vaccination of animals. Foot-and-mouth disease (FMD) is highly contagious among cloven-hoofed animals, like cattle, swine, sheep, and goats, as well as many species of wild animals. Thus, increasing incidences of livestock diseases are the major factors driving the growth of the veterinary vaccines market, as these diseases can be eradicated with the periodic use of vaccines for animals.

Other factors, which are driving the veterinary vaccines market growth, are rising incidence of zoonotic diseases and initiatives taken by government agencies, animal associations, and leading players.

Key Market Trends

Companion Animal Vaccines Segment is Expected to Show Better Growth in the Forecast Period

Veterinary vaccines are used primarily for livestock, as they suffer from various diseases, such as bluetongue virus, foot-and-mouth disease (FMD), and rabies. However, the companion vaccine is expected to witness high growth, over the forecast period. Vaccination has long been a principal point of canine practice, as it is one of the safest and most cost-effective means of infectious disease prevention.

According to the annual report of the European Pet Food Industry Association (FEDIAF) for 2020, dogs and cats are the major pets adopted in Europe. Moreover, an estimate of 85 million European households owns at least one pet animal. The trend is further expected to enhance during the forecast period, owing to the factors, such as pet humanization, and the rapid adoption of pets in emerging economies. the rising adoption of pets increases the vaccination programs of the companion animals boosting the segment growth.

The rapid proliferation of companion animal vaccines, advancement in diagnostic services and vaccine technology, and concerns over vaccine safety have contributed to the strong growth of the segment. Moreover, the market is being positively affected by evolving vaccine protocols with continuously changing patterns of diseases and the pet population.

North America Dominates the Veterinary Vaccines Market

North America holds the largest market share. Veterinary vaccines in the United States are regulated by the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS). The CVB grants establishment and product license to animal health companies, in order to manufacture and sell veterinary biologics.

In the United States, advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. For instance, in January 2020, Zoetis, a leading animal health company has further expanded its poultry vaccine portfolio with the introduction of Poulvac Procerta HVT-ND, a vectored recombinant vaccine for protection against Newcastle and Marek’s disease viruses.

Vaccination, in companion and wildlife animals for zoonotic diseases, had a great impact on reducing the incidence of zoonotic diseases. Furthermore, the rising awareness about the prevention of diseases and technological advancements are expected to propel the demand for veterinary vaccine in the region.

Competitive Landscape

The veterinary vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and they are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion animals.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

ページTOPに戻る

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Livestock Diseases
4.2.2 Increasing Pet Adoption Globally
4.2.3 Initiatives by Government Agencies, Animal Associations, and Leading Players
4.3 Market Restraints
4.3.1 High Storage Costs for Vaccines
4.3.2 Shortage of Veterinarians and Skilled Farm Workers
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Vaccine Type
5.1.1 Livestock Vaccines
5.1.1.1 Bovine Vaccines
5.1.1.2 Poultry Vaccines
5.1.1.3 Porcine Vaccines
5.1.1.4 Other Livestock Vaccines
5.1.2 Companion Animal Vaccines
5.1.2.1 Canine Vaccines
5.1.2.2 Feline Vaccines
5.1.2.3 Equine Vaccines
5.2 By Technology
5.2.1 Live Attenuated Vaccines
5.2.2 Inactivated Vaccines
5.2.3 Toxoid Vaccines
5.2.4 Recombinant Vaccines
5.2.5 Other Technologies
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis Inc.
6.1.2 Merck & Co. Inc.
6.1.3 Virbac
6.1.4 Hester Biosciences Limited
6.1.5 Elanco Animal Health
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Ceva Sante Animale
6.1.8 Phibro Animal Health Corporation
6.1.9 HIPRA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS